Table 5.
Increase in mean blood level values of peripheral blood S100B protein, nitrotyrosine (NTT), and O-myelin autoantibodies in EHS and/or MCS patients, according to References [10,11].
Patient Groups | ||||||||
---|---|---|---|---|---|---|---|---|
Markers Normal Values | EHS Mean ± SE | Above Normal (%) | MCS Mean ± SE | Above Normal (%) | p * | EHS/MCS Mean ± SE | Above Normal (%) | p ** |
S100B < 0.105 µg/L | 0.20 ± 0.03 | 14.7 | 0.25 ± 0.05 | 21.15 | 0.56 | 0.17 ± 0.03 | 19.7 | 0.69 |
NTT * > 0.9 µg/ml | 1.36 ± 0.12 | 29.7 | 1.26 ± 0.13 | 8 | 0.85 | 1.40 ± 0.12 | 28.9 | 0.86 |
O-myelin (qualitative test) | Positive | 22.8 | Positive | 13.6 | _ | Positive | 23.6 | _ |
* Comparison between the EHS and MCS groups of patients using the two-tailed t-test. There is no statistically significant difference between the two groups of EHS and MCS patients for increased mean level values of the two different biomarkers analyzed, suggesting that EHS and MCS share a common physiopathological mechanism for genesis. ** Comparison between the EHS and EHS/MCS groups of patients using the two-tailed t-test. There is no statistically significant difference between EHS and EHS/MCS patients for increased mean level values of the different biomarkers analyzed, suggesting here too that EHS and MCS share a common physiopathological mechanism for genesis.